Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 5/2012

01-10-2012 | Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

Anti-Inflammatory Therapy in Type 1 Diabetes

Authors: Bernd Baumann, Heba H. Salem, Bernhard O. Boehm

Published in: Current Diabetes Reports | Issue 5/2012

Login to get access

Abstract

Type 1 diabetes (T1D) is a multi-factorial, organ-specific autoimmune disease in genetically susceptible individuals, which is characterized by a selective and progressive loss of insulin-producing β-cells. Cells mediating innate as well as adaptive immunity infiltrate pancreatic islets, thereby generating an aberrant inflammatory process called insulitis that can be mirrored by a pathologic autoantibody production and autoreactive T-cells. In tight cooperation with infiltrating innate immune cells, which secrete high levels of pro-inflammatory cytokines like IL-1β, TNFα, and INFγ effector T-cells trigger the fatal destruction process of β-cells. There is ongoing discussion on the contribution of inflammation in T1D pathogenesis, ranging from a bystander reaction of autoimmunity to a dysregulation of immune responses that initiate inflammatory processes and thereby actively promoting β-cell death. Here, we review recent advances in anti-inflammatory interventions in T1D animal models and preclinical studies and discuss their mode of action as well as their capacity to interfere with T1D development.
Literature
1.
Mordes JP, Bortell R, Doukas J, Rigby M, Whalen B, et al. The BB/Wor rat and the balance hypothesis of autoimmunity. Diabetes Metab Rev. 1996;12:103–9.PubMed
2.
Anderson MS, Bluestone JA. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol. 2005;23:447–85.PubMedCrossRef
3.
Willcox A, Richardson SJ, Bone AJ, Foulis AK, Morgan NG. Analysis of islet inflammation in human type 1 diabetes. Clin Exp Immunol. 2009;155:173–81.PubMedCrossRef
4.
Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A. 2007;104:5115–20.PubMedCrossRef
5.
Uno S, Imagawa A, Okita K, Sayama K, Moriwaki M, et al. Macrophages and dendritic cells infiltrating islets with or without beta cells produce tumor necrosis factor-alpha in patients with recent-onset type 1 diabetes. Diabetologia. 2007;50:596–601.PubMedCrossRef
6.
•• Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, et al. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med. 2012;209:51–60. This study definitely provides evidence that human islets from T1D patients contain CD8 + T-cells with autoreactivity against either single or multiple islet autoantigens by using in situ tetramer staining.PubMedCrossRef
7.
• Richardson SJ, Willcox A, Bone AJ, Morgan NG, Foulis AK. Immunopathology of the human pancreas in type-I diabetes. Semin Immunopathol. 2011;33:9–21. This article is a comprehensive review on the immunohistopathologic features of human T1D pathogenesis which differs markedly compared with the NOD model.PubMedCrossRef
8.
Nejentsev S, Walker N, Riches D, Egholm M, Todd JA. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science. 2009;324:387–9.PubMedCrossRef
9.
Eizirik DL, Sammeth M, Bouckenooghe T, Bottu G, Sisino G, et al. The human pancreatic islet transcriptome: expression of candidate genes for type 1 diabetes and the impact of pro-inflammatory cytokines. PLoS Genet. 2012;8:e1002552.PubMedCrossRef
10.
Sarkar SA, Lee CE, Victorino F, Nguyen TT, Walters JA, et al. Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes. 2012;61:436–46.PubMedCrossRef
11.
Fairfax BP, Makino S, Radhakrishnan J, Plant K, Leslie S, et al. Genetics of gene expression in primary immune cells identifies cell type-specific master regulators and roles of HLA alleles. Nat Genet. 2012;44:502–10.PubMedCrossRef
12.
Tersey SA, Nishiki Y, Templin AT, Cabrera SM, Stull ND, et al. Islet beta-cell endoplasmic reticulum stress precedes the onset of type 1 diabetes in the non-obese diabetic mouse model. Diabetes. 2012;61:818–27.PubMedCrossRef
13.
Baker RG, Hayden MS, Ghosh S. NF-κB, inflammation, and metabolic disease. Cell Metab. 2011;13:11–22.PubMedCrossRef
14.
15.
Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene. 2006;25:6685–705.PubMedCrossRef
16.
Polychronakos C, Li Q. Understanding type 1 diabetes through genetics: advances and prospects. Nat Rev Genet. 2011;12:781–92.PubMedCrossRef
17.
Hegazy DM, O'Reilly DA, Yang BM, Hodgkinson AD, Millward BA, et al. NFκB polymorphisms and susceptibility to type 1 diabetes. Genes Immun. 2001;2:304–8.PubMedCrossRef
18.
Berchtold LA, Storling ZM, Ortis F, Lage K, Bang-Berthelsen C, et al. Huntingtin-interacting protein 14 is a type 1 diabetes candidate protein regulating insulin secretion and beta-cell apoptosis. Proc Natl Acad Sci U S A. 2011;108:E681–8.PubMedCrossRef
19.
Katarina K, Daniela P, Peter N, Marianna R, Pavlina C, et al. HLA, NFκB1, and NFKBIA gene polymorphism profile in autoimmune diabetes mellitus patients. Exp Clin Endocrinol Diabetes. 2007;115:124–9.PubMedCrossRef
20.
Guo D, Li M, Zhang Y, Yang P, Eckenrode S, et al. A functional variant of SUMO4, a new IκB alpha modifier, is associated with type 1 diabetes. Nat Genet. 2004;36:837–41.PubMedCrossRef
21.
Ouaaz F, Arron J, Zheng Y, Choi Y, Beg AA. Dendritic cell development and survival require distinct NF-κB subunits. Immunity. 2002;16:257–70.PubMedCrossRef
22.
Martin E, O'Sullivan B, Low P. Thomas R Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity. 2003;18:155–67.PubMedCrossRef
23.
Moore F, Buonocore S, Aksoy E, Ouled-Haddou N, Goriely S, et al. An alternative pathway of NF-κB activation results in maturation and T cell priming activity of dendritic cells overexpressing a mutated IκBα. J Immunol. 2007;178:1301–11.PubMed
24.
Lamhamedi-Cherradi SE, Zheng S, Hilliard BA, Xu L, Sun J, et al. Transcriptional regulation of type I diabetes by NF-κ B. J Immunol. 2003;171:4886–92.PubMed
25.
Mabley JG, Hasko G, Liaudet L, Soriano FG, Southan GJ, et al. NFκB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes. J Endocrinol. 2002;173:457–64.PubMedCrossRef
26.
Weaver Jr DJ, Poligone B, Bui T, Abdel-Motal UM, Baldwin Jr AS, et al. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-κB regulation due to a hyperactive IκB kinase. J Immunol. 2001;167:1461–8.PubMed
27.
Poligone B, Weaver Jr DJ, Sen P, Baldwin Jr AS, Tisch R. Elevated NF-κB activation in non-obese diabetic mouse dendritic cells results in enhanced APC function. J Immunol. 2002;168:188–96.PubMed
28.
Wheat W, Kupfer R, Gutches DG, Rayat GR, Beilke J, et al. Increased NF-κ B activity in B cells and bone marrow-derived dendritic cells from NOD mice. Eur J Immunol. 2004;34:1395–404.PubMedCrossRef
29.
Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science. 1995;268:1185–8.PubMedCrossRef
30.
Boothby MR, Mora AL, Scherer DC, Brockman JA, Ballard DW. Perturbation of the T lymphocyte lineage in transgenic mice expressing a constitutive repressor of nuclear factor (NF)-κB. J Exp Med. 1997;185:1897–907.PubMedCrossRef
31.
Wan YY, DeGregori J. The survival of antigen-stimulated T cells requires NFκB-mediated inhibition of p73 expression. Immunity. 2003;18:331–42.PubMedCrossRef
32.
Dale E, Davis M, Faustman DL. A role for transcription factor NF-κB in autoimmunity: possible interactions of genes, sex, and the immune response. Adv Physiol Educ. 2006;30:152–8.PubMedCrossRef
33.
Schreck R, Baeuerle PA. NF-κ B as inducible transcriptional activator of the granulocyte-macrophage colony-stimulating factor gene. Mol Cell Biol. 1990;10:1281–6.PubMed
34.
Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-κB/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705–8.PubMed
35.
Sen P, Bhattacharyya S, Wallet M, Wong CP, Poligone B, et al. NF-κ B hyperactivation has differential effects on the APC function of non-obese diabetic mouse macrophages. J Immunol. 2003;170:1770–80.PubMed
36.
Liou HC, Hsia CY. Distinctions between c-Rel and other NF-κB proteins in immunity and disease. Bioessays. 2003;25:767–80.PubMedCrossRef
37.
38.
Marino E, Silveira PA, Stolp J, Grey ST. B cell-directed therapies in type 1 diabetes. Trends Immunol. 2011;32:287–94.PubMedCrossRef
39.
Rahman A, Fazal F. Blocking NF-κB: an inflammatory issue. Proc Am Thorac Soc. 2012;8:497–503.CrossRef
40.
Gerondakis S, Grumont R, Gugasyan R, Wong L, Isomura I, et al. Unraveling the complexities of the NF-κB signaling pathway using mouse knockout and transgenic models. Oncogene. 2006;25:6781–99.PubMedCrossRef
41.
Vlantis K, Pasparakis M. Role of TNF in pathologies induced by nuclear factor κB deficiency. Curr Dir Autoimmun. 2010;11:80–93.PubMedCrossRef
42.
Schmidt A, Oberle N, Krammer PH. Molecular mechanisms of treg-mediated T cell suppression. Front Immunol. 2012;3:51.PubMed
43.
Patel S, Santani D. Role of NF-κ B in the pathogenesis of diabetes and its associated complications. Pharmacol Rep. 2009;61:595–603.PubMed
44.
Zhao Y, Krishnamurthy B, Mollah ZU, Kay TW, Thomas HE. NF-κB in type 1 diabetes. Inflamm Allergy Drug Targets. 2011;10:208–17.PubMed
45.
Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes. 2005;54 Suppl 2:S97–107.PubMedCrossRef
46.
Eizirik DL, Mandrup-Poulsen T. A choice of death–the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia. 2001;44:2115–33.PubMedCrossRef
47.
Cardozo AK, Heimberg H, Heremans Y, Leeman R, Kutlu B, et al. A comprehensive analysis of cytokine-induced and nuclear factor-κ B-dependent genes in primary rat pancreatic beta cells. J Biol Chem. 2001;276:48879–86.PubMedCrossRef
48.
Giannoukakis N, Rudert WA, Trucco M, Robbins PD. Protection of human islets from the effects of interleukin-1beta by adenoviral gene transfer of an IκB repressor. J Biol Chem. 2000;275:36509–13.PubMedCrossRef
49.
Heimberg H, Heremans Y, Jobin C, Leemans R, Cardozo AK, et al. Inhibition of cytokine-induced NF-κB activation by adenovirus-mediated expression of a NF-κB super-repressor prevents beta-cell apoptosis. Diabetes. 2001;50:2219–24.PubMedCrossRef
50.
Chang I, Kim S, Kim JY, Cho N, Kim YH, et al. Nuclear factor κB protects pancreatic beta cells from tumor necrosis factor-α-mediated apoptosis. Diabetes. 2003;52:1169–75.PubMedCrossRef
51.
Thomas HE, Angstetra E, Fernandes RV, Mariana L, Irawaty W, et al. Perturbations in nuclear factor-κB or c-Jun N-terminal kinase pathways in pancreatic beta cells confer susceptibility to cytokine-induced cell death. Immunol Cell Biol. 2006;84:20–7.PubMedCrossRef
52.
Kim S, Millet I, Kim HS, Kim JY, Han MS, et al. NF-κB prevents beta-cell death and autoimmune diabetes in NOD mice. Proc Natl Acad Sci U S A. 2007;104:1913–8.PubMedCrossRef
53.
Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, et al. IL-1beta and IFN-gamma induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia. 2003;46:255–66.PubMed
54.
Kutlu B, Darville MI, Cardozo AK, Eizirik DL. Molecular regulation of monocyte chemoattractant protein-1 expression in pancreatic beta cells. Diabetes. 2003;52:348–55.PubMedCrossRef
55.
Szkudelski T. The mechanism of alloxan and streptozotocin action in B cells of the rat pancreas. Physiol Res. 2001;50:537–46.PubMed
56.
Herold KC, Vezys V, Sun Q, Viktora D, Seung E, et al. Regulation of cytokine production during development of autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol. 1996;156:3521–7.PubMed
57.
Muller A, Schott-Ohly P, Dohle C, Gleichmann H. Differential regulation of Th1-type and Th2-type cytokine profiles in pancreatic islets of C57BL/6 and BALB/c mice by multiple low doses of streptozotocin. Immunobiology. 2002;205:35–50.PubMedCrossRef
58.
Manikandan R, Thiagarajan R, Beulaja S, Sivakumar MR, Meiyalagan V, et al. 1, 2 di-substituted idopyranose from Vitex negundo l. Protects against streptozotocin-induced diabetes by inhibiting nuclear factor-κB and inducible nitric oxide synthase expression. Microsc Res Tech. 2011;74:301–7.
59.
Song MY, Jeong GS, Kwon KB, Ka SO, Jang HY, et al. Sulfuretin protects against cytokine-induced beta-cell damage and prevents streptozotocin-induced diabetes. Exp Mol Med. 2010;42:628–38.PubMedCrossRef
60.
Kwon KB, Kim EK, Jeong ES, Lee YH, Lee YR, et al. Cortex cinnamomi extract prevents streptozotocin- and cytokine-induced beta-cell damage by inhibiting NF-κB. World J Gastroenterol. 2006;12:4331–7.PubMed
61.
Yuan HD, Chung SH. Fermented ginseng protects streptozotocin-induced damage in rat pancreas by inhibiting nuclear factor-κB. Phytother Res. 2010;24 Suppl 2:S190–5.PubMedCrossRef
62.
63.
Hu CM, Li JS, Cheah KP, Lin CW, Yu WY, et al. Effect of Sanguis draconis (a dragon's blood resin) on streptozotocin- and cytokine-induced beta-cell damage, in vitro and in vivo. Diabetes Res Clin Pract. 2011;94:417–25.PubMedCrossRef
64.
•• Ueberberg S, Deutschbein T, Klein HH, Dietrich JW, Akinturk S, et al. Protection from diabetes development by single-chain antibody-mediated delivery of a NF-κB inhibitor specifically to beta-cells in vivo. Am J Physiol Endocrinol Metab. 2011;301:E83–90. The authors show for the first time the highly selective, noninvasive delivery of a fusion protein into beta cells, which allows for the cell type specific inhibition of NF-κB in the context of MLDS-induced diabetes. New delivery strategies for peptide inhibitors in major inflammatory signaling components can be developed.PubMedCrossRef
65.
Eldor R, Yeffet A, Baum K, Doviner V, Amar D, et al. Conditional and specific NF-κB blockade protects pancreatic beta cells from diabetogenic agents. Proc Natl Acad Sci U S A. 2006;103:5072–7.PubMedCrossRef
66.
Schott-Ohly P, Lgssiar A, Partke HJ, Hassan M, Friesen N, et al. Prevention of spontaneous and experimentally induced diabetes in mice with zinc sulfate-enriched drinking water is associated with activation and reduction of NF-κ B and AP-1 in islets, respectively. Exp Biol Med (Maywood). 2004;229:1177–85.
67.
Bellenger J, Bellenger S, Bataille A, Massey KA, Nicolaou A, et al. High pancreatic n-3 fatty acids prevent STZ-induced diabetes in fat-1 mice: inflammatory pathway inhibition. Diabetes. 2011;60:1090–9.PubMedCrossRef
68.
Norlin S, Ahlgren U, Edlund H. Nuclear factor-κB activity in beta-cells is required for glucose-stimulated insulin secretion. Diabetes. 2005;54:125–32.PubMedCrossRef
69.
Koulmanda M, Budo E, Bonner-Weir S, Qipo A, Putheti P, et al. Modification of adverse inflammation is required to cure new-onset type 1 diabetic hosts. Proc Natl Acad Sci U S A. 2007;104:13074–9.PubMedCrossRef
70.
Thomas HE, Irawaty W, Darwiche R, Brodnicki TC, Santamaria P, et al. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes. 2004;53:113–21.PubMedCrossRef
71.
Lee SM, Yang H, Tartar DM, Gao B, Luo X, et al. Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes. Diabetologia. 2011;54:1136–46.PubMedCrossRef
72.
Gonzalez R, Ballester I, Lopez-Posadas R, Suarez MD, Zarzuelo A, et al. Effects of flavonoids and other polyphenols on inflammation. Crit Rev Food Sci Nutr. 2012;51:331–62.CrossRef
73.
• Maier B, Ogihara T, Trace AP, Tersey SA, Robbins RD, et al. The unique hypusine modification of eIF5A promotes islet beta-cell inflammation and dysfunction in mice. J Clin Invest. 2010;120:2156–70. The authors identify a novel, highly specific “druggable” target enzyme in beta cells, which is critically involved in the regulation of inflammatory processes in pancreatic islets.PubMedCrossRef
74.
Ruan Q, Wang T, Kameswaran V, Wei Q, Johnson DS, et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta-cell death. Proc Natl Acad Sci U S A. 2011;108:12030–5.PubMedCrossRef
75.
Lipton R, LaPorte RE, Becker DJ, Dorman JS, Orchard TJ, et al. Cyclosporin therapy for prevention and cure of IDDM. Epidemiological perspective of benefits and risks. Diabetes Care. 1990;13:776–84.PubMedCrossRef
76.
Blonska M, Lin X. NF-κB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res. 2011;21:55–70.PubMedCrossRef
77.
Thome M, Charton JE, Pelzer C, Hailfinger S. Antigen receptor signaling to NF-κB via CARMA1, BCL10, and MALT1. Cold Spring Harb Perspect Biol. 2010;2:a003004.PubMedCrossRef
78.
Palkowitsch L, Marienfeld U, Brunner C, Eitelhuber A, Krappmann D, et al. The Ca2 + -dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-κB activation. J Biol Chem. 2011;286:7522–34.PubMedCrossRef
79.
von Noorden C, Die Zuckerkrankheit und ihre Behandlung. In: Hirschwald A, editor. Behandlung mit Arzneimitteln. 5. edition ed. 1910;258–67.
80.
Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, et al. Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler Thromb Vasc Biol. 2006;26:2567–73.PubMedCrossRef
81.
Tehrani S, Mobarrez F, Antovic A, Santesson P, Lins PE, et al. Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res. 2010;126:e225–31.PubMedCrossRef
82.
Tehrani S, Antovic A, Mobarrez F, Mageed K, Lins PE, et al. High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes. Diabetes Care. 2012;35:404–8.PubMedCrossRef
83.
Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(κ)B kinase-beta. Nature. 1998;396:77–80.PubMedCrossRef
84.
85.
Kanda H, Yokota K, Kohno C, Sawada T, Sato K, et al. Effects of low-dosage simvastatin on rheumatoid arthritis through reduction of Th1/Th2 and CD4/CD8 ratios. Mod Rheumatol. 2007;17:364–8.PubMedCrossRef
86.
McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomized placebo-controlled trial. Lancet. 2004;363:2015–21.PubMedCrossRef
87.
Tang TT, Song Y, Ding YJ, Liao YH, Yu X, et al. Atorvastatin up-regulates regulatory T cells and reduces clinical disease activity in patients with rheumatoid arthritis. J Lipid Res. 2011;52:1023–32.PubMedCrossRef
88.
Martin S, Herder C, Schloot NC, Koenig W, Heise T, et al. Residual beta-cell function in newly diagnosed type 1 diabetes after treatment with atorvastatin: the Randomized DIATOR Trial. PLoS One. 2011;6:e17554.PubMedCrossRef
89.
Strom A, Kolb H, Martin S, Herder C, Simon MC, et al. Improved preservation of residual beta-cell function by atorvastatin in patients with recent onset type 1 diabetes and high CRP levels (DIATOR trial). PLoS One. 2012;7:e33108.PubMedCrossRef
90.
Beyan H, Riese H, Hawa MI, Beretta G, Davidson HW, et al. Glycotoxin and autoantibodies are additive environmentally determined predictors of type 1 diabetes: a twin and population study. Diabetes. 2012;61:1192–8.PubMedCrossRef
91.
Fleming TH, Humpert PM, Nawroth PP, Bierhaus A. Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: a mini-review. Gerontology. 2011;57:435–43.PubMed
92.
Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, et al. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med. 2007;7:743–51.PubMedCrossRef
93.
Bierhaus A, Nawroth PP. Multiple levels of regulation determine the role of the receptor for AGE (RAGE) as common soil in inflammation, immune responses and diabetes mellitus and its complications. Diabetologia. 2009;52:2251–63.PubMedCrossRef
94.
Vlassara H, Striker G. Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep. 2007;7:235–41.PubMedCrossRef
95.
Peppa M, He C, Hattori M, McEvoy R, Zheng F, et al. Fetal or neonatal low-glycotoxin environment prevents autoimmune diabetes in NOD mice. Diabetes. 2003;52:1441–8.PubMedCrossRef
96.
Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, et al. Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci. 2007;62:427–33.PubMedCrossRef
97.
Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, et al. The role of oxidative stress and NF-κB activation in late diabetic complications. Biofactors. 1999;10:157–67.PubMedCrossRef
98.
Goraca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, et al. Lipoic acid - biological activity and therapeutic potential. Pharmacol Rep. 2011;63:849–58.PubMed
99.
Forbes JM, Soderlund J, Yap FY, Knip M, Andrikopoulos S, et al. Receptor for advanced glycation end-products (RAGE) provides a link between genetic susceptibility and environmental factors in type 1 diabetes. Diabetologia. 2012;54:1032–42.CrossRef
100.
•• Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol. 2010;6:158–66. This review extensively analyses and discusses the distinct functions of IL-1 in T1D development and highlights the rationales for blocking IL-1 action in T1D patients.PubMedCrossRef
Metadata
Title
Anti-Inflammatory Therapy in Type 1 Diabetes
Authors
Bernd Baumann
Heba H. Salem
Bernhard O. Boehm
Publication date
01-10-2012
Publisher
Current Science Inc.
Published in
Current Diabetes Reports / Issue 5/2012
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-012-0299-y

Other articles of this Issue 5/2012

Current Diabetes Reports 5/2012 Go to the issue

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Adipose Tissue, Hormones, and Treatment of Type 1 Diabetes

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Continuous Glucose Monitoring in Children and Adolescents

Transplantation (A Pileggi, Section Editor)

Harnessing the Immunomodulatory and Tissue Repair Properties of Mesenchymal Stem Cells to Restore β Cell Function

Transplantation (A Pileggi, Section Editor)

Autologous Regulatory T Cells for the Treatment of Type 1 Diabetes

Treatment of Type 1 Diabetes (D Dabelea, Section Editor)

Stem Cell Educator Therapy and Induction of Immune Balance

Pathogenesis of Type 1 Diabetes (AG Ziegler, Section Editor)

Treg Vaccination with a Strong-Agonistic Insulin Mimetope
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits